Edoc Acquisition Corp. Class A Ordinary Share (ADOC) News
Filter ADOC News Items
ADOC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ADOC News From Around the Web
Below are the latest news stories about Edoc Acquisition Corp that investors may wish to consider to help them evaluate ADOC as an investment opportunity.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ADOC, CHWA, PTRS, AZPNNEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a shareholder rights law firm, announces it is investigating the following companies concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to: Edoc Acquisition Corp. (NASDAQ: ADOC )''s merger with Calidi Biotherapeutics, Inc. If you are an Edoc shareholder, click here to learn more about your rights and options . CHW Acquisition Corporation (NASDAQ: CHWA )''s merger with Wag Labs, Inc. If you are a CHWA shareholder, click here to learn more about your rights and options . Partners Bancorp (NASDAQ: PTRS )''s sale to OceanFirst Financial Corp. Under Full story available on Benzinga.com |
Edoc Acquisition Corp. Reminds Shareholders to Vote in Favor of Extension AmendmentNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, and ADOCW) (“Edoc” or the “Company”) encourages its shareholders to vote in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from February 12, 2022 to August 12, 2022 (the “Extension”). An extraordinary general meeting of the Company’s shareholders (“Special Meeting”) to approve the Extension Amendment will b |
Calidi Biotherapeutics in deal to go public through SPAC Edoc AcquisitionCalidi Biotherapeutics agreed to go public through a deal with Edoc Acquisition Corp |
Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through multiple clinical milestones- -Business combination expected to be completed in second quarter of 2022- LA JOLLA, CALIF. and Victor, NY, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Co |
EDOC Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business CombinationVictor, NY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (NASDAQ: ADOC) (the “Company”), announced today that an aggregate of $900,000 (the “Extension Payment”) has been deposited into the Company’s trust account for its public shareholders, representing $0.10 per public share, which enables the Company to extend the period of time it has to consummate its initial business combination by three months from November 12, 2021 to February 12, 2022 (the “Extension”). The Extension is the first of up to two three-month extensions permitted under the Company’s governing documents. |
EDOC Acquisition Corp. Announces Sponsor Approval of Extension of Deadline to Complete Business CombinationVictor, NY, Nov. 09, 2021 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (NASDAQ: ADOC) (the Company), a publicly traded special purpose acquisition company, announced today that its sponsor, American Physicians LLC (the Sponsor), has requested that the Company extend the date by which the Company has to consummate a business combination from November 12, 2021 to February 12, 2022 (the Extension). The Extension is the first of up to two three-month extensions permitted under the Companys governing documents. In connection with such Extension, the Sponsor has notified the Company that it intends to cause an aggregate of $900,000 to be deposited into the Companys trust account on or before November 12, 2021. |
Berkley W R Corp Sells 112,943 Shares of Edoc Acquisition Corp. (NASDAQ:ADOC)Berkley W R Corp reduced its stake in Edoc Acquisition Corp. (NASDAQ:ADOC) by 23.7% during the second quarter, Holdings Channel.com reports. The fund owned 363,730 shares of the companys stock after selling 112,943 shares during the quarter. Berkley W R Corps holdings in Edoc Acquisition were worth $4,704,000 at the end of the most recent [] |
Do Insiders Own Lots Of Shares In Edoc Acquisition Corp. (NASDAQ:ADOC)?If you want to know who really controls Edoc Acquisition Corp. ( NASDAQ:ADOC ), then you'll have to look at the makeup... |
Edoc Acquisition Corp. Receives Expected Notice from Nasdaq Regarding Delayed Annual ReportNew York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (NASDAQ: ADOC) (the “Company”) announced today that it received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Form 10-K”) with the Securities and Exchange Commission (“SEC”). The Notice has no immediate effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Form 8-K filed on April 15, 2021 by the Company, on April 12, 2021, the staff (the “Staff”) of the Division of Corp... |